Brind.
  1. A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
  2. FDA granted Fast Track designation to Allarity Therapeutics' drug, led by CEO Thomas Jensen.

Allarity Therapeutics, led by CEO Thomas Jensen, is advancing its drug stenoparib toward U.S. regulatory approval and holds pending patent applications in China, India, and Japan.

3 reports, 1 independent Updated Sep 15
Gone quiet
Reports
3
Developments
2
Repetition
33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Allarity Therapeutics, led by CEO Thomas Jensen, is advancing its drug stenoparib toward U.S. regulatory approval and holds pending patent applications in China, India, and Japan.

Who's involved

What this event is mainly about
Thomas JensenChina

How it developed

Newest first. Tap a step to see who reported it.
  1. Allarity Therapeutics secured patent protection in Europe.1 source
  2. Allarity seeks U.S. regulatory approval and holds pending patents in China, India, and Japan.

Keep exploring

Part of

FDA granted Fast Track designation to Allarity Therapeutics' drug, led by CEO Thomas Jensen. All 1 developments

Within A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.

The entities involved

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story